Literature DB >> 35523526

Updates in Molecular Breast Imaging.

Carrie B Hruska1.   

Abstract

Molecular breast imaging (MBI) is a nuclear medicine study performed with dedicated gamma camera systems optimized to image the uptake of Tc-99m sestamibi in the breast. MBI provides a relatively low-cost and simple functional breast imaging method that can identify breast cancers obscured by dense fibroglandular tissue on mammography. Recent studies have also found that background levels of uptake in benign dense tissue may provide breast cancer risk information. This article discusses the latest updates in MBI technology, recent evidence supporting its clinical use, and work in progress that may aid in wider adoption of MBI.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 35523526      PMCID: PMC9077005          DOI: 10.1053/j.ro.2021.12.006

Source DB:  PubMed          Journal:  Semin Roentgenol        ISSN: 0037-198X            Impact factor:   0.709


  22 in total

1.  Diagnostic workup and costs of a single supplemental molecular breast imaging screen of mammographically dense breasts.

Authors:  Carrie B Hruska; Amy Lynn Conners; Katie N Jones; Michael K O'Connor; James P Moriarty; Judy C Boughey; Deborah J Rhodes
Journal:  AJR Am J Roentgenol       Date:  2015-06       Impact factor: 3.959

2.  Let's Get Real about Molecular Breast Imaging and Radiation Risk.

Authors:  Carrie B Hruska
Journal:  Radiol Imaging Cancer       Date:  2019-09-27

3.  Guidelines for Quality Control Testing of Molecular Breast Imaging Systems.

Authors:  Sara M Nardinger; Thuy D Tran; Tiffinee N Swanson; Lacey R Ellingson; Courtney M Solberg; Michael K O'Connor; Carrie B Hruska
Journal:  J Nucl Med Technol       Date:  2018-06-08

4.  Curies, and Grays, and Sieverts, Oh My: A Guide for Discussing Radiation Dose and Risk of Molecular Breast Imaging.

Authors:  Carrie B Hruska; Michael K O'Connor
Journal:  J Am Coll Radiol       Date:  2015-10       Impact factor: 5.532

5.  Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine.

Authors:  E B Silberstein; J Ryan
Journal:  J Nucl Med       Date:  1996-01       Impact factor: 10.057

6.  To use MIBI or not to use MIBI? That is the question when assessing tumour cells.

Authors:  Jean-Luc Moretti; Nathalie Hauet; Meltem Caglar; Olivier Rebillard; Zeynep Burak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

7.  Factors influencing the uptake of 99mTc-sestamibi in breast tissue on molecular breast imaging.

Authors:  Michael K O'Connor; Carrie B Hruska; Thuy D Tran; Tiffinee Swanson; Amy Lynn Conners; Katie Jones; Deborah J Rhodes
Journal:  J Nucl Med Technol       Date:  2015-01-22

8.  Background Parenchymal Uptake on Molecular Breast Imaging and Breast Cancer Risk: A Cohort Study.

Authors:  Carrie B Hruska; Jennifer R Geske; Amy Lynn Conners; Dana H Whaley; Deborah J Rhodes; Michael K O'Connor; Rickey E Carter; Christopher G Scott; Celine M Vachon
Journal:  AJR Am J Roentgenol       Date:  2021-03-03       Impact factor: 3.959

9.  Breast cancer detection with Tc-99m tetrofosmin.

Authors:  P F Rambaldi; L Mansi; E Procaccini; F Di Gregorio; E Del Vecchio
Journal:  Clin Nucl Med       Date:  1995-08       Impact factor: 7.794

10.  Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors.

Authors:  Martin Andersson; Lennart Johansson; David Minarik; Sigrid Leide-Svegborn; Sören Mattsson
Journal:  EJNMMI Phys       Date:  2014-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.